DE60128899D1 - Verwendung eines botulinumtoxins zur herstellung eines arzneimittels zur peripheren behandlung von schmerzen, die nicht mit muskelspasmen oder kopfschmerzen in verbindung stehen - Google Patents
Verwendung eines botulinumtoxins zur herstellung eines arzneimittels zur peripheren behandlung von schmerzen, die nicht mit muskelspasmen oder kopfschmerzen in verbindung stehenInfo
- Publication number
- DE60128899D1 DE60128899D1 DE60128899T DE60128899T DE60128899D1 DE 60128899 D1 DE60128899 D1 DE 60128899D1 DE 60128899 T DE60128899 T DE 60128899T DE 60128899 T DE60128899 T DE 60128899T DE 60128899 D1 DE60128899 D1 DE 60128899D1
- Authority
- DE
- Germany
- Prior art keywords
- spas
- headache
- pain
- medicament
- muscle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Revoked
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US550371 | 2000-04-14 | ||
US09/550,371 US6464986B1 (en) | 2000-04-14 | 2000-04-14 | Method for treating pain by peripheral administration of a neurotoxin |
PCT/US2001/011836 WO2001078760A2 (en) | 2000-04-14 | 2001-04-11 | Method for treating pain by peripheral administration of a neurotoxin |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60128899D1 true DE60128899D1 (de) | 2007-07-26 |
DE60128899T2 DE60128899T2 (de) | 2008-02-21 |
Family
ID=24196890
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60142590T Expired - Lifetime DE60142590D1 (de) | 2000-04-14 | 2001-04-11 | Verwendung von Botulinum Toxin zur Behandlung von post-operative Schmerzen |
DE60128899T Revoked DE60128899T2 (de) | 2000-04-14 | 2001-04-11 | Verwendung eines botulinumtoxins zur herstellung eines arzneimittels zur peripheren behandlung von schmerzen, die nicht mit muskelspasmen oder kopfschmerzen in verbindung stehen |
DE60143061T Expired - Lifetime DE60143061D1 (de) | 2000-04-14 | 2001-04-11 | Verwendung von Botulinum Toxin zur Behandlung von Gelenkschmerzen |
DE60141230T Expired - Lifetime DE60141230D1 (de) | 2000-04-14 | 2001-04-11 | Verwendung von Botulinum Toxin zur Behandlung von neuralgischen Schmerzen |
DE60143549T Expired - Lifetime DE60143549D1 (de) | 2000-04-14 | 2001-04-11 | Verwendung von Botulinum Toxin zur Behandlung von durch Infektion verursachtem Schmerz |
DE60142712T Expired - Lifetime DE60142712D1 (de) | 2000-04-14 | 2001-04-11 | Verwendung von Botulinum Toxin zur Behandlung von Eingweideschmerzen |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60142590T Expired - Lifetime DE60142590D1 (de) | 2000-04-14 | 2001-04-11 | Verwendung von Botulinum Toxin zur Behandlung von post-operative Schmerzen |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60143061T Expired - Lifetime DE60143061D1 (de) | 2000-04-14 | 2001-04-11 | Verwendung von Botulinum Toxin zur Behandlung von Gelenkschmerzen |
DE60141230T Expired - Lifetime DE60141230D1 (de) | 2000-04-14 | 2001-04-11 | Verwendung von Botulinum Toxin zur Behandlung von neuralgischen Schmerzen |
DE60143549T Expired - Lifetime DE60143549D1 (de) | 2000-04-14 | 2001-04-11 | Verwendung von Botulinum Toxin zur Behandlung von durch Infektion verursachtem Schmerz |
DE60142712T Expired - Lifetime DE60142712D1 (de) | 2000-04-14 | 2001-04-11 | Verwendung von Botulinum Toxin zur Behandlung von Eingweideschmerzen |
Country Status (19)
Country | Link |
---|---|
US (14) | US6464986B1 (de) |
EP (7) | EP1604681B1 (de) |
JP (1) | JP4037652B2 (de) |
KR (1) | KR20030009431A (de) |
CN (1) | CN1188165C (de) |
AR (1) | AR030209A1 (de) |
AT (6) | ATE473753T1 (de) |
AU (2) | AU2001251546B9 (de) |
BR (1) | BR0110030A (de) |
CA (3) | CA2485919A1 (de) |
CY (2) | CY1108065T1 (de) |
DE (6) | DE60142590D1 (de) |
DK (6) | DK1604678T3 (de) |
ES (7) | ES2349782T3 (de) |
MX (1) | MXPA02009932A (de) |
NZ (1) | NZ521535A (de) |
PT (2) | PT1604680E (de) |
TW (1) | TWI282282B (de) |
WO (1) | WO2001078760A2 (de) |
Families Citing this family (158)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6974578B1 (en) * | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
TW574036B (en) * | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
US20060216313A1 (en) * | 1999-08-10 | 2006-09-28 | Allergan, Inc. | Methods for treating a stricture with a botulinum toxin |
US6767544B2 (en) | 2002-04-01 | 2004-07-27 | Allergan, Inc. | Methods for treating cardiovascular diseases with botulinum toxin |
US6977080B1 (en) * | 1999-08-10 | 2005-12-20 | Allergan, Inc. | Intrapericardial botulinum toxin treatment for bradycardia |
US7838008B2 (en) * | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
US6464986B1 (en) * | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
US20040033241A1 (en) * | 2000-06-02 | 2004-02-19 | Allergan, Inc. | Controlled release botulinum toxin system |
US20040170665A1 (en) * | 2000-06-02 | 2004-09-02 | Allergan, Inc. | Intravitreal botulinum toxin implant |
AU2001270219A1 (en) * | 2000-06-28 | 2002-01-08 | Ira Sanders | Methods for using tetanus toxin for benificial purposes in animals (mammals) |
US20040219619A1 (en) * | 2000-07-21 | 2004-11-04 | Ester Fernandez-Salas | Methods of identifying compounds that alter toxin persistence and/or protease activity |
US7491799B2 (en) * | 2000-07-21 | 2009-02-17 | Allergan, Inc. | Modified botulinum neurotoxins |
US7691983B2 (en) * | 2000-07-21 | 2010-04-06 | Allergan, Inc. | Chimera botulinum toxin type E |
US6903187B1 (en) * | 2000-07-21 | 2005-06-07 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
US6423319B1 (en) * | 2000-10-04 | 2002-07-23 | Allergan Sales, Inc. | Methods for treating muscle injuries |
US20020086036A1 (en) * | 2000-12-05 | 2002-07-04 | Allergan Sales, Inc. | Methods for treating hyperhidrosis |
ITUD20010002A1 (it) * | 2001-01-05 | 2002-07-05 | Univ Degli Studi Udine | Uso della tossina botulinica per la soluzione di patologie articolari, in particolare della coxartrosi, della epicondilite e della patolo |
US20020192239A1 (en) * | 2001-01-09 | 2002-12-19 | Borodic Gary E. | Use of botulinum toxin for the treatment of chronic facial pain |
JP4707254B2 (ja) * | 2001-04-24 | 2011-06-22 | クミアイ化学工業株式会社 | 粒状組成物及びその製造方法 |
WO2002089794A1 (en) * | 2001-05-07 | 2002-11-14 | Universite Catholique De Louvain | Method for treating neuropathic pain and pharmaceutical preparation therefor |
US7374896B2 (en) * | 2001-08-28 | 2008-05-20 | Allergan, Inc. | GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity |
EP1443932B1 (de) * | 2001-11-15 | 2012-12-26 | Micro Algae Corporation | Pharmazeutische zusammensetzungen mit 3,4-propinoperhydropurinen und ihre verwendung zur blockierung der neuronalen übertragung |
US7763663B2 (en) * | 2001-12-19 | 2010-07-27 | University Of Massachusetts | Polysaccharide-containing block copolymer particles and uses thereof |
US6921538B2 (en) * | 2002-05-10 | 2005-07-26 | Allergan, Inc. | Therapeutic treatments for neuropsychiatric disorders |
EP1523307A1 (de) * | 2002-07-19 | 2005-04-20 | Mestex AG | Verwendung von neurotoxischen substanzen für die herstellung eines mittels zur behandlung von gelenkschmerzen und verfahren zur applikation dieses mittels |
CA2501856A1 (en) * | 2002-10-15 | 2004-04-29 | Allergan, Inc. | Botulinum toxin dental therapies and procedures |
US7238357B2 (en) * | 2002-11-05 | 2007-07-03 | Allergan, Inc. | Methods for treating ulcers and gastroesophageal reflux disease |
US20040086532A1 (en) * | 2002-11-05 | 2004-05-06 | Allergan, Inc., | Botulinum toxin formulations for oral administration |
WO2004076634A2 (en) * | 2003-02-24 | 2004-09-10 | Ira Sanders | Cell membrane translocation of regulated snare inhibitors , compositions therefor, and methods for treatment of disease |
MXPA05009425A (es) * | 2003-03-06 | 2006-02-10 | Botulinum Toxin Res Ass Inc | Tratamiento del dolor facial cronico y cefalea relacionados con la sinusitis con toxina botulinica. |
CA2518155A1 (en) * | 2003-03-06 | 2004-09-16 | Botulinum Toxin Research Associates, Inc. | Treatment of chronic chalazion and hordeolum with botulinum toxin |
WO2004078200A1 (en) * | 2003-03-06 | 2004-09-16 | Botulinum Toxin Research Associates, Inc. | Selection of patients with increased responsiveness to botulinum toxin |
GB2400316A (en) * | 2003-04-10 | 2004-10-13 | Richard Markoll | Electromagnetic stimulation in patients with osteoporosis |
US7393538B2 (en) * | 2003-04-25 | 2008-07-01 | Ackerman Alan H | Clostridial toxin treatment for dermatillomania |
US7393537B2 (en) | 2003-04-25 | 2008-07-01 | Allergan, Inc. | Botulinum toxin for treatment of obsessive compulsive finger biting disorder |
US7396535B2 (en) * | 2003-04-25 | 2008-07-08 | Ackerman Alan H | Therapy for obsessive compulsive head banging |
US7390496B2 (en) * | 2003-04-25 | 2008-06-24 | Allergan, Inc. | Therapeutic treatments for repetitive hand washing |
US7422753B2 (en) * | 2003-04-25 | 2008-09-09 | Allergan, Inc. | Methods for treating trichotillomania |
US6838434B2 (en) * | 2003-05-02 | 2005-01-04 | Allergan, Inc. | Methods for treating sinus headache |
US7220422B2 (en) * | 2003-05-20 | 2007-05-22 | Allergan, Inc. | Methods and compositions for treating eye disorders |
US20040253274A1 (en) * | 2003-06-11 | 2004-12-16 | Allergan, Inc. | Use of a clostridial toxin to reduce appetite |
US8617572B2 (en) | 2003-10-29 | 2013-12-31 | Allergan, Inc. | Botulinum toxin treatments of depression |
US8734810B2 (en) * | 2003-10-29 | 2014-05-27 | Allergan, Inc. | Botulinum toxin treatments of neurological and neuropsychiatric disorders |
US8609113B2 (en) | 2003-10-29 | 2013-12-17 | Allergan, Inc. | Botulinum toxin treatments of depression |
US8609112B2 (en) | 2003-10-29 | 2013-12-17 | Allergan, Inc. | Botulinum toxin treatments of depression |
US7172764B2 (en) * | 2003-11-17 | 2007-02-06 | Allergan, Inc. | Rescue agents for treating botulinum toxin intoxications |
US8048423B2 (en) * | 2003-12-09 | 2011-11-01 | Allergan, Inc. | Botulinum toxin therapy for skin disorders |
US8871224B2 (en) * | 2003-12-09 | 2014-10-28 | Allergan, Inc. | Botulinum toxin therapy for skin disorders |
US20050129677A1 (en) * | 2003-12-10 | 2005-06-16 | Shengwen Li | Lipid rafts and clostridial toxins |
US20050148935A1 (en) * | 2003-12-29 | 2005-07-07 | Rozalina Dimitrova | Botulinum toxin injection guide |
US7270287B2 (en) * | 2004-01-06 | 2007-09-18 | Allergan, Inc. | Botulinum toxin treatment for kinesia |
US6974579B2 (en) * | 2004-01-08 | 2005-12-13 | Allergan, Inc. | Methods for treating vascular disorders |
US20100266638A1 (en) * | 2004-02-26 | 2010-10-21 | Allergan, Inc. | Headache treatment method |
US20050191321A1 (en) * | 2004-02-26 | 2005-09-01 | Allergan, Inc. | Methods for treating headache |
US9078892B2 (en) * | 2004-02-26 | 2015-07-14 | Allergan, Inc. | Methods for treating pain and for treating a medication overuse disorder |
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
US20050220821A1 (en) * | 2004-03-31 | 2005-10-06 | Allergan, Inc. | Pressure sore treatment |
US20050220734A1 (en) * | 2004-04-02 | 2005-10-06 | Allergan, Inc. | Therapy for melanin related afflictions |
ES2646087T3 (es) * | 2004-05-07 | 2017-12-12 | Algenis Spa | Ficotoxinas y sus usos. |
US8377951B2 (en) * | 2004-05-07 | 2013-02-19 | Phytotox Limited | Transdermal administration of phycotoxins |
KR100668570B1 (ko) * | 2004-06-28 | 2007-01-16 | 입센 리미티드 | 복재신경 포착에 의한 무릎 관절 통증 치료를 위한,보툴리눔 독소를 포함하는 제약 조성물 |
US6991789B2 (en) * | 2004-06-29 | 2006-01-31 | Allergas, Inc. | Methods of modulating intracellular degradation rates of toxins |
US7922983B2 (en) * | 2005-07-28 | 2011-04-12 | Kimberly-Clark Worldwide, Inc. | Sterilization wrap with additional strength sheet |
US7811584B2 (en) * | 2004-06-30 | 2010-10-12 | Allergan, Inc. | Multivalent clostridial toxins |
US7514088B2 (en) * | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
GB2417419A (en) * | 2004-07-12 | 2006-03-01 | Ipsen Ltd | Therapeutic use of Botulinum toxin |
US20060024794A1 (en) * | 2004-07-30 | 2006-02-02 | Shengwen Li | Novel methods for production of di-chain botulinum toxin |
US20060024331A1 (en) * | 2004-08-02 | 2006-02-02 | Ester Fernandez-Salas | Toxin compounds with enhanced membrane translocation characteristics |
AU2005279741B2 (en) | 2004-09-01 | 2011-10-06 | Allergan, Inc. | Degradable clostridial toxins |
US7179474B2 (en) * | 2004-09-03 | 2007-02-20 | Allergan, Inc. | Methods for treating a buttock deformity |
US7429386B2 (en) * | 2004-09-03 | 2008-09-30 | Allergan, Inc. | Stretch mark treatment |
US8343929B2 (en) | 2004-09-23 | 2013-01-01 | Toxcure, Inc. | Treating neoplasms with neurotoxin |
WO2006034404A2 (en) | 2004-09-23 | 2006-03-30 | Toxcure, Inc. | Treating neoplasms with neurotoxin |
US20060073208A1 (en) * | 2004-10-01 | 2006-04-06 | Allergan, Inc. | Cosmetic neurotoxin compositions and methods |
US7897147B2 (en) * | 2004-10-20 | 2011-03-01 | Allergan, Inc. | Treatment of premenstrual disorders |
FR2879462B1 (fr) * | 2004-12-21 | 2008-12-26 | Sod Conseils Rech Applic | Utilisation de toxine botulique pour une insensibilisation locale prolongee |
US7749515B2 (en) | 2005-02-01 | 2010-07-06 | Allergan, Inc. | Targeted delivery of botulinum toxin to the sphenopalatine ganglion |
US7655244B2 (en) | 2005-02-01 | 2010-02-02 | Allergan, Inc. | Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions |
BRPI0508299A (pt) | 2005-03-03 | 2007-07-31 | Allergan Inc | sistema livre de produto animal e processo para purificação de uma toxina botulina |
CA2601577A1 (en) | 2005-03-15 | 2006-09-21 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
WO2008036060A2 (en) | 2005-04-05 | 2008-03-27 | Allergan, Inc. | Clostridial toxin activity assays |
US7419675B2 (en) * | 2005-05-26 | 2008-09-02 | Allergan, Inc. | Method for treating peritoneal adhesions |
US20060269574A1 (en) * | 2005-05-31 | 2006-11-30 | De Beer Johann F | Method of repairing tendons by surgery |
US8926991B2 (en) | 2005-06-14 | 2015-01-06 | Botulinum Toxin Research Associates, Inc. | Botulinum toxin and the treatment of primary disorders of mood and affect |
EP1898947A2 (de) * | 2005-06-14 | 2008-03-19 | Botulinum Toxin Research Associates, Inc. | Botulinustoxin und behandlung von primären stimmungs- und affekt-erkrankungen |
US20150258183A1 (en) | 2006-06-07 | 2015-09-17 | Botulinum Toxin Research Associates, Inc. | Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect |
US8105611B2 (en) * | 2005-06-17 | 2012-01-31 | Allergan, Inc. | Treatment of autoimmune disorder with a neurotoxin |
JP5368793B2 (ja) | 2005-07-18 | 2013-12-18 | ユニバーシティ オブ マサチューセッツ ロウエル | ナノエマルジョンを製造および使用するための組成物および方法 |
US7910116B2 (en) * | 2005-08-24 | 2011-03-22 | Allergan, Inc. | Use of a botulinum toxin to improve gastric emptying and/or to treat GERD |
US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
TR201901443T4 (tr) | 2005-12-01 | 2019-02-21 | Univ Massachusetts Lowell | Botulinum nanoemülsiyonları. |
US7824694B2 (en) * | 2006-01-12 | 2010-11-02 | Allergan, Inc. | Methods for enhancing therapeutic effects of a neurotoxin |
US20070178121A1 (en) * | 2006-01-27 | 2007-08-02 | Allergan, Inc. | Methods for enhancing skin treatments |
US7794386B2 (en) | 2006-03-15 | 2010-09-14 | Allergan, Inc. | Methods for facilitating weight loss |
US20080021437A1 (en) * | 2006-04-27 | 2008-01-24 | Boyd James P | Enhancement of the efficacy of a clenching reduction device by augmenting with botulinum toxin type A |
US7811586B2 (en) * | 2006-05-02 | 2010-10-12 | Allergan, Inc. | Methods for alleviating testicular pain |
CN101074935B (zh) * | 2006-05-19 | 2011-03-23 | 清华大学 | 探测器阵列及设备 |
FR2902341B1 (fr) | 2006-06-16 | 2011-02-25 | Scras | Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace |
US9061025B2 (en) * | 2006-08-31 | 2015-06-23 | Allergan, Inc. | Methods for selecting headache patients responsive to botulinum toxin therapy |
US20080092910A1 (en) * | 2006-10-18 | 2008-04-24 | Allergan, Inc. | Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures |
FR2907680B1 (fr) * | 2006-10-27 | 2012-12-28 | Scras | Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux |
US20080113051A1 (en) * | 2006-11-13 | 2008-05-15 | Allergan, Inc. | Methods for alleviating tattoo pain |
BRPI0719732A2 (pt) | 2006-12-01 | 2017-05-16 | Anterios Inc | nanopartículas de peptídeo e usos para as mesmas |
EP2494958A1 (de) * | 2006-12-01 | 2012-09-05 | Anterios, Inc. | Nanopartikel aus amphiphilen Einheiten |
FR2910327B1 (fr) | 2006-12-22 | 2013-04-26 | Scras | Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida. |
ES2520765T3 (es) * | 2007-02-15 | 2014-11-11 | Allergan, Inc. | Uso de toxina botulínica para el tratamiento de hiperhidrosis |
ES2660906T3 (es) | 2007-05-31 | 2018-03-26 | Anterios, Inc. | Nanopartículas de ácido nucleico y usos de las mismas |
DE102007038015A1 (de) * | 2007-08-10 | 2009-02-19 | Hefter, Harald, Prof. Dr. med. Dr. rer. nat. | Verwendung eines Neurotoxins |
JP2009132672A (ja) * | 2007-10-31 | 2009-06-18 | Okayama Univ | ボツリヌス毒素由来のポリペプチドを有効成分として含む鎮痛作用を有する医薬組成物 |
US8470337B2 (en) * | 2008-03-13 | 2013-06-25 | Allergan, Inc. | Therapeutic treatments using botulinum neurotoxin |
US8617571B2 (en) | 2008-04-03 | 2013-12-31 | Allergan, Inc. | Suture line administration technique using botulinum toxin |
FR2930447B1 (fr) | 2008-04-25 | 2010-07-30 | Sod Conseils Rech Applic | Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique |
WO2009158687A1 (en) * | 2008-06-26 | 2009-12-30 | Anterios, Inc. | Dermal delivery |
ES2356883B1 (es) * | 2008-07-24 | 2012-02-22 | Bcn Peptides, S.A. | Composición para el tratamiento del dolor y/o la inflamación. |
US20100028385A1 (en) * | 2008-08-04 | 2010-02-04 | Allergan, Inc. | Treatment of excess cerumen secretion |
WO2010016901A1 (en) * | 2008-08-05 | 2010-02-11 | Solstice Neurosciences, Inc. | Compositions of activated botulinum holotoxin type b (150 kd) |
EP2315598A1 (de) * | 2008-08-05 | 2011-05-04 | Solstice Neurosciences, Inc. | Zusammensetzungen aus aktiviertem botulintoxin vom typ b |
WO2010051039A1 (en) * | 2008-11-03 | 2010-05-06 | Solstice Neurosciences, Inc. | Compositions of activated botulinum toxin type b |
US20100112006A1 (en) * | 2008-11-03 | 2010-05-06 | Solstice Neurosciences, Inc. | Compositions of activated botulinum holotoxin type B (150 kD) |
AU2010221435B2 (en) | 2009-03-06 | 2014-06-19 | Allergan, Inc. | Clostridial toxin to improve ejaculate |
CA2774951C (en) | 2009-09-24 | 2014-12-16 | Allergan, Inc. | Method of treating osteoporosis with a neurotoxin |
CN102892454B (zh) | 2010-01-26 | 2016-01-20 | 迈克尔·A·埃文斯 | 用于去神经支配的方法、装置以及药剂 |
JP2011157331A (ja) * | 2010-02-03 | 2011-08-18 | Chemo-Sero-Therapeutic Research Inst | 高用量投与が可能なボツリヌス毒素製剤 |
WO2012103415A1 (en) | 2011-01-28 | 2012-08-02 | Allergan, Inc. | Dosage regimen for the treatment of multiple disorders with botulinum toxins |
US8697090B2 (en) | 2011-05-05 | 2014-04-15 | Allergan, Inc. | Method of treating persistent genital arousal disorder with a neurotoxin |
US8992941B2 (en) | 2011-07-08 | 2015-03-31 | Allergan, Inc. | Method for treatment of esophageal spasm |
AU2012282873B2 (en) | 2011-07-08 | 2016-03-31 | Allergan, Inc. | Method for treatment of autonomic nervous system disorders |
BR112014000634A2 (pt) | 2011-07-14 | 2017-02-14 | Allergan Inc | métodos para tratamento de incontinência associada com atividade sexual |
MX2014000612A (es) | 2011-07-20 | 2014-02-27 | Allergan Inc | Toxinas botulinicas para usar en un metodo para el tratamiento de depositos adiposos. |
ES2424294B1 (es) | 2012-03-22 | 2014-07-21 | Lipotec, S.A. | Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas |
EP2649984A1 (de) | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Verbindungen zur Hemmung neuronaler Exozytose |
EP2649983A1 (de) | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Verbindungen zur Hemmung neuronaler Exozytose (II) |
AU2013246882B2 (en) | 2012-04-13 | 2017-10-19 | Lubrizol Advanced Materials, Inc. | Compounds which inhibit neuronal exocytosis (II) |
EP2649985A1 (de) | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Verbindungen zur Hemmung neuronaler Exozytose (III) |
US9005628B2 (en) | 2012-10-04 | 2015-04-14 | Dublin City University | Biotherapy for pain |
KR20150135425A (ko) | 2013-03-22 | 2015-12-02 | 리포텍 에스.에이. | 피부, 점막 및/또는 손톱의 치료 및/또는 관리를 위한 세포외 다당류 |
GB201312317D0 (en) | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
US10149893B2 (en) | 2013-09-24 | 2018-12-11 | Allergan, Inc. | Methods for modifying progression of osteoarthritis |
US9480731B2 (en) | 2013-12-12 | 2016-11-01 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
US9216210B2 (en) | 2013-12-23 | 2015-12-22 | Dublin City University | Multiprotease therapeutics for chronic pain |
WO2016040039A1 (en) * | 2014-09-12 | 2016-03-17 | Allergan, Inc. | Methods for treating osteoarthritis pain |
PL3242884T3 (pl) | 2015-01-09 | 2021-08-16 | Ipsen Bioinnovation Limited | Kationowe neurotoksyny |
CA2999279A1 (en) * | 2015-10-01 | 2017-04-06 | Goleini Inc. | Targeted expression of chloride channels and methods of use thereof |
GB201517450D0 (en) | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
GB201607901D0 (en) | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
EP3263710A1 (de) | 2016-07-01 | 2018-01-03 | Ipsen Biopharm Limited | Herstellung von aktivierten clostridien-neurotoxinen |
WO2018038301A1 (en) | 2016-08-26 | 2018-03-01 | Hugel Inc. | Stabilized liquid formulation of botulinum toxin and preparation method thereof |
EP3519430A1 (de) | 2016-09-29 | 2019-08-07 | Ipsen Biopharm Limited | Hybridneurotoxine |
KR102487144B1 (ko) | 2016-11-21 | 2023-01-12 | 에이리온 테라퓨틱스, 인코포레이티드 | 큰 물질의 경피 전달 |
CN110913868A (zh) * | 2017-05-24 | 2020-03-24 | Atgc 股份有限公司 | 用于治疗足痛疾病的包括肉毒杆菌毒素和透明质酸的药物组合物以及使用其治疗足痛疾病的方法 |
EP3470054B1 (de) | 2017-10-11 | 2023-09-20 | Hugel Inc. | Mikrostrukturformulierungstechniken für botulinumtoxin |
US10792400B2 (en) | 2017-10-12 | 2020-10-06 | Hugel Inc. | Microstructure formulation techniques for botulinum toxin |
US10525111B2 (en) | 2017-10-12 | 2020-01-07 | Hugel, Inc. | Microstructure formulation techniques for botulinum toxin |
EP3758611A1 (de) | 2018-02-26 | 2021-01-06 | Ipsen Biopharm Limited | Verwendung von ultraschall zur führung der injektion von nichttoxischer protease |
LT3660509T (lt) | 2018-11-29 | 2022-05-10 | Hugel Inc. | Ląstelių panaudojimu paremtas būdas botulino toksino aktyvumui nustatyti |
GB202011055D0 (en) * | 2020-07-17 | 2020-09-02 | Ipsen Bioinnovation Ltd | Treatment of post-operative pain |
GB202103372D0 (en) | 2021-03-11 | 2021-04-28 | Ipsen Biopharm Ltd | Modified clostridial neurotoxins |
WO2024069191A1 (en) | 2022-09-30 | 2024-04-04 | Ipsen Biopharm Limited | Clostridial neurotoxin for use in a treatment of bladder pain syndrome |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2693207B1 (fr) * | 1992-07-03 | 1994-09-30 | Orsan | Souche de levure permettant la co-expression d'une activité mono-oxygénase de cytochrome P450 hétérologue et d'une NADPH-cytochrome P450-réductase endogène ou hétérologue et son utilisation à des fins de bioconversion. |
EP0679090A1 (de) | 1993-01-15 | 1995-11-02 | Interactive Biologics Associates | Verfahren zur behandlung von gesichtsmuskel schmez syndrom |
US5592212A (en) * | 1993-04-16 | 1997-01-07 | News Datacom Ltd. | Methods and systems for non-program applications for subscriber television |
AU688452B2 (en) * | 1993-12-28 | 1998-03-12 | Allergan, Inc. | Botulinum toxins for treating various disorders and associated pain |
US5766605A (en) | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
ATE292977T1 (de) | 1994-05-09 | 2005-04-15 | William J Binder | Präsynaptische neurotoxine gegen migränekopfschmerzen |
GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
JPH08306853A (ja) * | 1995-05-09 | 1996-11-22 | Fujitsu Ltd | 半導体装置及びその製造方法及びリードフレームの製造方法 |
US5721215A (en) | 1996-03-20 | 1998-02-24 | Allergan | Injectable therapy for control of muscle spasms and pain related to muscle spasms |
GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
US6063768A (en) | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
GB9721189D0 (en) | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
US6113915A (en) | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
US6261572B1 (en) * | 2000-01-11 | 2001-07-17 | Allergan Sales, Inc. | Method for treating a pancreatic disorder with a neurotoxin |
US20010036943A1 (en) * | 2000-04-07 | 2001-11-01 | Coe Jotham W. | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
US6464986B1 (en) | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
EP1763315A4 (de) | 2004-07-07 | 2009-03-04 | Obstecare Inc | Verfahren zur überwachung von geburtsprozessen |
-
2000
- 2000-04-14 US US09/550,371 patent/US6464986B1/en not_active Expired - Lifetime
-
2001
- 2001-04-11 EP EP05006625A patent/EP1604681B1/de not_active Expired - Lifetime
- 2001-04-11 DE DE60142590T patent/DE60142590D1/de not_active Expired - Lifetime
- 2001-04-11 ES ES05006625T patent/ES2349782T3/es not_active Expired - Lifetime
- 2001-04-11 ES ES05006626T patent/ES2394314T3/es not_active Expired - Lifetime
- 2001-04-11 AT AT05006622T patent/ATE473753T1/de not_active IP Right Cessation
- 2001-04-11 AT AT05006624T patent/ATE456375T1/de active
- 2001-04-11 EP EP05006622A patent/EP1604678B1/de not_active Expired - Lifetime
- 2001-04-11 DE DE60128899T patent/DE60128899T2/de not_active Revoked
- 2001-04-11 DK DK05006622.4T patent/DK1604678T3/da active
- 2001-04-11 DE DE60143061T patent/DE60143061D1/de not_active Expired - Lifetime
- 2001-04-11 DE DE60141230T patent/DE60141230D1/de not_active Expired - Lifetime
- 2001-04-11 EP EP05006623A patent/EP1604679B1/de not_active Expired - Lifetime
- 2001-04-11 CA CA002485919A patent/CA2485919A1/en not_active Abandoned
- 2001-04-11 EP EP05006626A patent/EP1550456B1/de not_active Expired - Lifetime
- 2001-04-11 KR KR1020027013536A patent/KR20030009431A/ko not_active Application Discontinuation
- 2001-04-11 DK DK05006623.2T patent/DK1604679T3/da active
- 2001-04-11 PT PT05006624T patent/PT1604680E/pt unknown
- 2001-04-11 CA CA002406367A patent/CA2406367C/en not_active Expired - Lifetime
- 2001-04-11 DE DE60143549T patent/DE60143549D1/de not_active Expired - Lifetime
- 2001-04-11 MX MXPA02009932A patent/MXPA02009932A/es active IP Right Grant
- 2001-04-11 ES ES05006622T patent/ES2347256T3/es not_active Expired - Lifetime
- 2001-04-11 AT AT05006625T patent/ATE480253T1/de not_active IP Right Cessation
- 2001-04-11 AT AT01924939T patent/ATE364393T1/de active
- 2001-04-11 ES ES05006624T patent/ES2338238T3/es not_active Expired - Lifetime
- 2001-04-11 DK DK05006624.0T patent/DK1604680T3/da active
- 2001-04-11 AU AU2001251546A patent/AU2001251546B9/en not_active Expired
- 2001-04-11 DK DK01924939T patent/DK1272207T3/da active
- 2001-04-11 CN CNB018109454A patent/CN1188165C/zh not_active Expired - Fee Related
- 2001-04-11 AT AT05006623T patent/ATE475427T1/de not_active IP Right Cessation
- 2001-04-11 NZ NZ521535A patent/NZ521535A/en not_active IP Right Cessation
- 2001-04-11 PT PT01924939T patent/PT1272207E/pt unknown
- 2001-04-11 ES ES05006627T patent/ES2353878T3/es not_active Expired - Lifetime
- 2001-04-11 AU AU5154601A patent/AU5154601A/xx active Pending
- 2001-04-11 ES ES05006623T patent/ES2347792T3/es not_active Expired - Lifetime
- 2001-04-11 AT AT05006627T patent/ATE489102T1/de not_active IP Right Cessation
- 2001-04-11 JP JP2001576060A patent/JP4037652B2/ja not_active Expired - Lifetime
- 2001-04-11 DK DK05006627.3T patent/DK1576963T3/da active
- 2001-04-11 DK DK05006625.7T patent/DK1604681T3/da active
- 2001-04-11 ES ES01924939T patent/ES2287117T3/es not_active Expired - Lifetime
- 2001-04-11 EP EP05006627A patent/EP1576963B1/de not_active Expired - Lifetime
- 2001-04-11 BR BR0110030-0A patent/BR0110030A/pt not_active Application Discontinuation
- 2001-04-11 EP EP05006624A patent/EP1604680B1/de not_active Expired - Lifetime
- 2001-04-11 AR ARP010101723A patent/AR030209A1/es unknown
- 2001-04-11 CA CA002485920A patent/CA2485920A1/en not_active Abandoned
- 2001-04-11 DE DE60142712T patent/DE60142712D1/de not_active Expired - Lifetime
- 2001-04-11 EP EP01924939A patent/EP1272207B1/de not_active Revoked
- 2001-04-11 WO PCT/US2001/011836 patent/WO2001078760A2/en active IP Right Grant
- 2001-04-13 TW TW090108937A patent/TWI282282B/zh not_active IP Right Cessation
-
2002
- 2002-07-18 US US10/199,222 patent/US6869610B2/en not_active Expired - Lifetime
-
2003
- 2003-07-29 US US10/630,204 patent/US20040018212A1/en not_active Abandoned
- 2003-07-29 US US10/630,206 patent/US7361358B2/en not_active Expired - Lifetime
- 2003-07-29 US US10/630,587 patent/US7172763B2/en not_active Expired - Lifetime
- 2003-07-29 US US10/630,604 patent/US7211262B2/en not_active Expired - Lifetime
-
2004
- 2004-09-15 US US10/943,133 patent/US7288260B2/en not_active Expired - Lifetime
- 2004-12-03 US US11/003,677 patent/US7067137B2/en not_active Expired - Lifetime
-
2005
- 2005-08-16 US US11/205,380 patent/US7294339B2/en not_active Expired - Lifetime
- 2005-08-16 US US11/205,357 patent/US20060039916A1/en not_active Abandoned
- 2005-08-16 US US11/205,596 patent/US7291344B2/en not_active Expired - Lifetime
- 2005-08-18 US US11/205,670 patent/US7276245B2/en not_active Expired - Lifetime
-
2006
- 2006-06-02 US US11/445,517 patent/US7374769B2/en not_active Expired - Lifetime
-
2007
- 2007-08-28 CY CY20071101123T patent/CY1108065T1/el unknown
- 2007-11-20 US US11/942,985 patent/US7468189B2/en not_active Expired - Fee Related
-
2010
- 2010-04-09 CY CY20101100322T patent/CY1109972T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60128899D1 (de) | Verwendung eines botulinumtoxins zur herstellung eines arzneimittels zur peripheren behandlung von schmerzen, die nicht mit muskelspasmen oder kopfschmerzen in verbindung stehen | |
DE69435330D1 (de) | Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen | |
DE60138549D1 (de) | Topische gel-abgabesysteme zur behandlung von hauterkrankungen | |
BG108443A (en) | Substituted oxazoliidinones for combinational therapy | |
SE9401406D0 (sv) | Pharmaceutical products for curing tumourous diseases and process for preparing same | |
DE60142839D1 (de) | Botulinum Toxin zur Behandlung von akuten Verletzungen der Skelettmuskeln | |
ATE312636T1 (de) | Infusion von flüssigkeiten in den menschlichen oder tierischen körper | |
DE60109589D1 (de) | Pharmazeutische zusammensetzung zur behandlung von akutem schmerz, chronischem schmerz und/oder neuropathischem schmerz und migräne | |
CY1109191T1 (el) | Μια νεα χρηση της δεφεριπρονης | |
WO2004096216A3 (en) | Use of a topical medicament comprising riluzole | |
DE69910202D1 (de) | EGR-1 zur Herstellung eines Medikamentes zur Behandlung von Wunden | |
DE59914712D1 (de) | Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden | |
YU42298A (sh) | Upotreba olanzapina za pripremanje leka korisnog kod akutnog bola | |
RU2002129355A (ru) | Применение фульвестранта при лечении резистентного рака молочной железы | |
DE60128009D1 (de) | Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma | |
PT1272200E (pt) | Terapeuticas em doses fraccionadas com actividade de degradacao vascular | |
DE60216292D1 (de) | Calciumtrifluoracetat mit zytotoxischer wirkung | |
DE60027282D1 (de) | Verwendung von l-threo-methylphenidate zur Herstellung eines Medikaments für die Behandlung von Depression | |
ATE337783T1 (de) | Neue therapeutische verwendung eines derivates von thienylcyclohexylamine zur behandlung von schmerzen | |
RU4077U1 (ru) | Устройство для массажа | |
DE60222662D1 (de) | Verwendung von l-azetylcarnitin zur herstellung eines medikaments zur präventiven post-chirurgischen schmerzbehandlung | |
ITTV20020159A1 (it) | Medicamento fitoterapico per il trattamento delle piaghe da decubito e delle lesioni cutanee in genere ottenuto dalla combinazione di principi attivi contenuti in alcune piante. | |
KR200193398Y1 (ko) | 무좀치료용 스프레이 | |
EA200501514A1 (ru) | Сочетания действующих веществ и способы лечения злоупотребления алкоголем | |
RU2003110183A (ru) | Способ лечения рассеянного склероза |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent | ||
8331 | Complete revocation |